中國衞生集團(00673.HK):建議更新發行公司新股份及購回股份的一般授權
格隆匯3月31日丨中國衞生集團(00673.HK)公佈,董事會建議更新現有一般授權以供董事(i)配發、發行或處理不超過有關決議案於股東特別大會獲通過當日已發行股份總數20%的新股份及(ii)在聯交所購回不超過有關決議案於股東特別大會獲通過當日已發行股份總數10%的股份。根據上市規則第13.36(4)條,批准授予經更新一般授權將須待獨立股東於公司股東大會上批准後,方可作實。
於股東周年大會上,股東已批准(其中包括)現有一般授權,其授權董事配發、發行或處理新股份不超過87,798,952股股份(即於有關決議案在股東周年大會上獲通過當日已發行股份總數的20%)以及在聯交所購回不超過43,899,476股股份(即於有關決議案在股東周年大會上獲通過當日已發行股份總數的10%)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.